Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 323

1.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE.

JAMA. 2002 Apr 3;287(13):1690-8.

PMID:
11926893
3.
4.

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Ma C, Zhang Y, Xu Q, Yang J, Zhang Y, Gao L, Xu B, Wang H, Li Y, Lu C, Yin T.

Int J Hematol. 2012 Dec;96(6):719-28. doi: 10.1007/s12185-012-1205-8. Epub 2012 Oct 27.

PMID:
23104259
5.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
6.

Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.

McMillin GA, Melis R, Wilson A, Strong MB, Wanner NA, Vinik RG, Peters CL, Pendleton RC.

Ther Drug Monit. 2010 Jun;32(3):338-45. doi: 10.1097/FTD.0b013e3181d925bb.

PMID:
20386359
7.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

8.

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.

Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R.

Eur J Clin Pharmacol. 2008 Jan;64(1):9-15. Epub 2007 Oct 23.

PMID:
17955230
9.

Pharmacogenetics of warfarin elimination and its clinical implications.

Takahashi H, Echizen H.

Clin Pharmacokinet. 2001;40(8):587-603. Review.

PMID:
11523725
10.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3.

PMID:
19077919
11.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
12.

Genetic modulation of oral anticoagulation with warfarin.

Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandone E, Di Minno G.

Thromb Haemost. 2000 Nov;84(5):775-8.

PMID:
11127854
13.

Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.

Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC.

Br J Haematol. 2012 Jul;158(2):256-61. doi: 10.1111/j.1365-2141.2012.09150.x. Epub 2012 May 10.

PMID:
22571356
14.

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM.

Eur J Clin Pharmacol. 2003 Jul;59(3):213-9. Epub 2003 May 1.

PMID:
12728288
15.

CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.

Peyvandi F, Spreafico M, Siboni SM, Moia M, Mannucci PM.

Clin Pharmacol Ther. 2004 Mar;75(3):198-203.

PMID:
15001971
16.

Association between the CYP2C9 polymorphism and the drug metabolism phenotype.

Topić E, Stefanović M, Samardzija M.

Clin Chem Lab Med. 2004 Jan;42(1):72-8.

PMID:
15061384
17.

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.

Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD.

J Am Coll Surg. 2002 Mar;194(3):267-73.

PMID:
11893129
18.

Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.

An SH, Lee KE, Chang BC, Gwak HS.

J Clin Pharm Ther. 2014 Jun;39(3):314-8. doi: 10.1111/jcpt.12143. Epub 2014 Mar 6.

PMID:
24602049
19.

Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.

Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S.

Eur J Pharmacol. 2013 Jun 15;710(1-3):80-4. doi: 10.1016/j.ejphar.2013.04.006. Epub 2013 Apr 16.

PMID:
23602689
20.

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.

Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A.

Clin Pharmacol Ther. 2004 Nov;76(5):409-17.

PMID:
15536456
Items per page

Supplemental Content

Write to the Help Desk